RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer-Reference-Cited by-同舟云学术

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

Published:2018-02-14 Issue:6 Volume:7 Page:e1431088
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ahern Elizabeth¹²,Harjunpää Heidi³⁴,O'Donnell Jake S.¹³⁴,Allen Stacey³,Dougall William C.¹⁵,Teng Michele W. L.³⁴,Smyth Mark J.¹⁴

Affiliation:

1. Department of Immunology, Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

2. Division of Cancer Care Services, Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

3. Department of Immunology, Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

4. Faculty of Medicine, University of Queensland, Herston, Queensland, Australia

5. Department of Immunology, Immuno-oncology Discovery Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

Funder

National Health and Medical Research Council (NHMRC)

Cancer Council Queensland

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1431088

Reference50 articles.

1. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases;Lung Cancer;2024-07

2. Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC);Journal for ImmunoTherapy of Cancer;2024-06

3. New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model;Cancer Immunology, Immunotherapy;2024-05-02

4. The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status;Biomedicines;2024-03-28

5. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy;Cellular and Molecular Life Sciences;2024-02-29